Ghahary lab (UBC) collagen papers
0 12 months1 3 yearsGhahary A[au] AND (collagen OR scaffold OR wound) New research, clinical studies and FDA 510(k) decisions in the lanes CXU competes in. Read from PubMed, ClinicalTrials.gov and openFDA.
Flowable collagen in wound care is the busiest research lane, with 164 papers in 12 months. FDA made 3 comparable 510(k) decisions in the last 6 months, ahead of Conexeu Sciences’ own 510(k) premarket notification, planned Q1 2027.
Turn the newest paper into an unbranded clinician explainer, and keep the 510(k) comparables list current for the submission.
CXU is an investigational medical device candidate in preclinical development. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. Safety and effectiveness have not been established.
Status line (rule R6): it travels with every mention of CXU. Copy it as written.
PubMed E-utilities, read Nov 12, 2026. Newest papers per query, linked to PubMed. 6 papers carry a date after the read: PubMed lists the journal issue date, which can be ahead of online publication.
Ghahary A[au] AND (collagen OR scaffold OR wound) (extracellular matrix[tiab] OR collagen scaffold[tiab]) AND (aesthetic*[tiab] OR facial[tiab] OR soft tissue augmentation[tiab]) (flowable[tiab] OR injectable[tiab] OR thermosensitive[tiab]) AND collagen[tiab] AND wound*[tiab] (semaglutide[tiab] OR tirzepatide[tiab] OR GLP-1[tiab]) AND (facial[tiab] OR skin laxity[tiab] OR soft tissue[tiab]) Flowable collagen in wound care is the busiest lane: 164 papers in 12 months, 337 in 3 years.
33 papers across the 4 queries are dated within 60 days of the read.
Ghahary lab (UBC) collagen papers: no paper in 12 months.
ClinicalTrials.gov API v2, read Nov 12, 2026. Registered studies matching each query, most recently updated first. A match on the query is not a judgement that the study is comparable.
flowable wound matrix OR injectable collagen wound collagen filler OR biostimulator OR extracellular matrix aesthetic breast reconstruction regenerative OR bioprinted breast openFDA device API, read Nov 12, 2026. Collagen wound dressings and flowable matrices: 11 decisions in 3 years. CXU itself has no FDA decision: see the status above.
Answers are computed from this client’s snapshots: headlines, topics, the site crawl, PubMed and openFDA. Click a day on any chart to see what was published around it.